Sarepta Therapeutics Reports Q2 Revenue Decline and Revised Outlook

PACS Group (NYSE: PACS) said it invested $191 million in owned real estate during the first half of 2026 and $104 million in the second quarter, citing a strong pipeline of nursing‑home acquisitions after returning to SEC reporting compliance. The company reported $756.6 million of available liquidity at quarter‑end.

CrossAmerica Partners (NYSE: CAPL) posted Q2 earnings of $0.52 per share, beating estimates, with revenue of $1.18 billion. The firm announced a $0.525 quarterly dividend and noted recent increases in holdings by several hedge funds.

Sarepta Therapeutics (NASDAQ: SRPT) recorded total Q2 revenue of $401 million, down 34% year over year, driven by weaker ELEVIDYS sales. GAAP operating income was $13 million and non‑GAAP operating income $86 million. Cash and investments rose to $945 million. New CEO Michael Severino highlighted the company’s Duchenne muscular dystrophy portfolio and revised its 2026 net product revenue outlook to $1.2‑$1.3 billion.

Certara (NASDAQ: CERT) reported Q2 2026 revenue of $93.3 million, a 1% increase, with software revenue up 4% and services revenue down 3%. The company posted a net loss of $6.1 million, completed a $100 million share‑repurchase program, and received board approval for an additional $50 million buyback. Expected run‑rate cost savings are about $13 million.

Pacific Biosciences of California (NASDAQ: PACB) held its Q2 2026 earnings call, presenting its financial results and forward‑looking statements, with senior executives and analysts participating.